The first oral ALK TKI approved for the treatment of ALK-positive NSCLC, crizotinib, initially showed encouraging results in the Phase 3 PROFILE 1014 study and resulted in drug use in patients with ALK-positive metastatic NSCLC [11]. Here, ALK is linked to non-small cell lung carcinoma.